FTC requiring Aurobindo Pharma to divest from four drug products to complete acquistion of Lannett

The US Federal Trade Commission has ordered Aurobindo Pharma to divest four generic drugs to complete its $250 million acquisition of Lannett Company Inc.

The ​U.S. Federal Trade Commission is requiring Aurobindo Pharma Limited to ‌divest four different generic drug products to complete its $250 million acquisition of Lannett Company Inc., the ‌agency said on Thursday in a statement.

The agency ‌will require Aurobindo to divest to Quagen Pharmaceuticals an immunosuppressant prescribed to prevent organ transplant rejection, a cholesterol ⁠management ​drug, ⁠a drug prescribed to treat dry mouth in radiation therapy ⁠patients and a drug prescribed to reduce stomach ​acid. "Aurobindo’s acquisition of Lannett would combine two ⁠of a limited number of competitors in the markets ⁠for ​four different generic pharmaceutical products that provide critical relief for patients, ranging from drugs ⁠used to prevent organ transplant rejection to tablets that ⁠treat ⁠dry mouth after radiation therapy," the FTC said.